Evercore ISI raised the firm’s price target on Immunome (IMNM) to $40 from $18 and keeps an Outperform rating on the shares. The “overwhelmingly positive” results from the RINGSIDE trial bolstered confidence in varegacestat’s potential as a leading treatment for desmoid tumors, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $35 from $25 at Guggenheim
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
- Immunome offers to sell $400M in common stock
- Immunome’s Promising Outlook: Buy Rating Affirmed on Varegacestat’s Phase 3 Success and Strong Management
- Immunome price target raised to $40 from $38 at Leerink